For best search results, use the search terms first and then apply the filters

The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until April, 2020.

  1. Advance Early Detection of Lupus Nephritis with ClearGold

    SBC: CLEARNANO INC            Topic: 400

    SummarySystemic lupus erythematosusSLEor lupus is an autoimmune disease that impacts more thanmillion people worldwideincludingmillion AmericansNearlyof these patients will develop lupus nephritiswhich can cause kidney failureAs a resultits financial burden to individual patient can reach $yearmuch higher than many other diseases because of kidney transplantationAlthough early treatment of lupus n ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  2. STTR Phase I Development of Novel Antibacterial and Antifungal Bioadhesive Biomaterials for Diabetic Skin Wound Healing

    SBC: Dynamic Entropy Technology, LLC            Topic: NIDDK

    Abstract Diabetic ulcers or pressure ulcers are common for patients with diabetesspinal cord injuriesetcWithout proper managementsuch wounds often lead to infections such as osteomyelitis or sepsisresulting in high mortality and morbidityIn addition to bacterial infectiondiabetic patients are also more susceptible to cutaneous fungal infectionsAdvanced wound dressings and advanced wound therapies ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  3. STTR Phase II: Deep Learning Technology For The Microscopic Analysis Of Stained Cells Using Unbiased Methods

    SBC: Stereology Resource Center, Inc            Topic: BT

    The broader impact/commercial potential of this Small Business Technology Transfer (STTR) Phase II project is the development of software to help bioscientists analyze more tissue in less time and with higher accuracy and reproducibility. Currently, stereology studies require a trained technician to sit before a computer screen, making tedious manual counts (clicks) on hundreds to thousands of mic ...

    STTR Phase II 2019 National Science Foundation
  4. Preclinical studies to validate the efficacy of novel mechanism-of-action small molecule inhibitors to treat Duchenne muscular dystrophy


    Progressive muscle weakness and degeneration is a hallmark of Duchenne muscular dystrophyDMDIn DMD patientsthe lack of dystrophin reduces muscle fiber structural integritymaking muscles vulnerable to persistent injury and damageRepairing these damaged muscles requires the continual activation of muscle stem cellsmuSCwhich leads to muSC dysfunction and senescenceand ultimately the muscle degenerati ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  5. Next Generation Tools for Onsite Monitoring and Treatment of Drug of Abuse-Dependent Persons

    SBC: SensoDX II, LLC            Topic: NIDA

    Abstract Opioid abuse disorderOADaffectsmillion of Americans annually resulting in overdoses numbering in the tens of thousands and skyrocketing rates of mortalityIn addition to its enormous social impactOAD carries a multi billion dollar price tag that includes $billionspecifically for health care and other costs related to prescription opioid abuse and misuseAlthough effective interventions exis ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health
  6. A high-efficiency, low-cost, single-use purification technology for therapeutic antibody manufacturing

    SBC: Bondwell Technologies Inc.            Topic: 400

    Therapeutic antibodies have had a profound impact on treatment of many types of cancer and autoimmune diseasesAs a resultfive of the top ten best selling drugs ofwere therapeutic antibodiesMore than seventy therapeutic antibodies have been approvedand over six hundred antibody based products are in clinical developmentHoweverantibodies are extremely expensive to produceand large amounts of antibod ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  7. STTR Phase I: Thermal Runaway and Pressure Suppression (TRAPS) for Lithium-Ion Batteries

    SBC: Altect, Inc.            Topic: CT

    The broader impact/commercial potential of this Small Business Innovation Research (SBIR) or STTR Phase I project is to develop and commercialize a technology to mitigate safety concerns associated with lithium-ion (Li-ion) battery technologies in electric vehicle, transportation, and energy storage applications. Li-ion battery technology is one of the most transformative innovations in the past d ...

    STTR Phase I 2019 National Science Foundation

    SBC: Nanosonic Inc.            Topic: N19BT030

    During the proposed Navy STTR program, NanoSonic and Virginia Tech will design and synthesize innovative, high strength ceramic nanocomposite microcapsules filled with > 80 volume percent water that are empirically optimized to function as readily dispersed powdered additives with long-term water retention, durability during air craft bladder production, and rupture during ballistic shock. NanoSon ...

    STTR Phase I 2019 Department of DefenseNavy
  9. Robust, Low Permeability, Water-Filled Microcapsules

    SBC: Luna Innovations Incorporated            Topic: N19BT030

    The Navy is actively developing a self-sealing, water-activated fuel bladder to mitigate fuel leaks upon mechanical shock (e.g. penetration by a .50 caliber bullet). To circumvent the requirement of an external water source to activate the self-sealing, this system will require water-filled microcapsules that can be incorporated directly into the polymeric matrix of the fuel bladder. Upon mechanic ...

    STTR Phase I 2019 Department of DefenseNavy
  10. Targeting glioblastoma stem-like cells with custom-designed viral vectors

    SBC: Lacerta Therapeutics, Inc.            Topic: 102

    GlioblastomaGBMis the most lethal form of adult brain cancers with a median survival of andltmonths despite aggressive standard chemoradiationGBM are formed by GBM stem like cellsGSCsa major contributor to tumor recurrence and a natural focus for therapeutic developmentThere are two main reasons responsible for treatment failurehigh intraand inter tumor cellular and molecular heterogeneity with mu ...

    STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health

Agency Micro-sites

SBA logo
Department of Agriculture logo
Department of Commerce logo
Department of Defense logo
Department of Education logo
Department of Energy logo
Department of Health and Human Services logo
Department of Homeland Security logo
Department of Transportation logo
Environmental Protection Agency logo
National Aeronautics and Space Administration logo
National Science Foundation logo
US Flag An Official Website of the United States Government